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The demonstration of circulating autoantibodies directed
against the constitutive desmosomal plaque proteins
desmoplakin (dp) I and II in mucocutaneous lesions in
a subset of patients with erythema multiforme major,
suggests that humoral immune mechanisms may play a
role in the pathogenesis of this severe skin disease. In
this study we identified a specific peptide sequence –
YSYSYS – representing an antigenic binding site for the
human autoantibodies. This epitope is localized at the
extreme carboxy terminal domain of dp thought to be
responsible for the assembly of keratin filaments with
desmosomes. To test the possibility whether these anti-
bodies may exert any pathologic effects in vivo, human
autoantibodies were affinity purified on a corresponding
synthetic peptide matrix and peptide-specific antibodies
were raised in rabbits. After repeated subcutaneous
Autoantibodies play a crucial role in the pathogenesisof autoimmune bullous diseases such as pemphigus,pemphigoid, epidermolysis bullosa acquisita, and bulloussystemic lupus erythematosus (Woodley et al, 1988;Gammon and Briggaman, 1993; Stanley, 1993). These
autoantibodies are all directed against proteins that are either within
cell–matrix adhesions, e.g., hemidesmosomes and anchoring fibrils
(Woodley et al, 1988; Domloge-Hultsch et al, 1992), or are part of
distinct cell–cell adhesion structures, the desmosomes (Garrod, 1993;
Stanley, 1993). In previous reports (Foedinger et al, 1995, 1996), we
have described a new type of autoantibodies in a subpopulation of
patients with erythema multiforme (EM) major that are directed against
desmoplakin (dp) I and II. These autoantibodies bind to the desmosomal
plaques of keratinocytes in lesional skin in vivo, where they localize to
the inner dense plaques of demosomes.
As in other epithelia, desmosomes of the epidermis are specialized
adhesion structures of cell membranes that consist of an extracellular
Manuscript received October 18, 1997; revised May 5, 1998; accepted for
publication May 21, 1998.
Reprint requests to: Dr. Klemens Rappersberger, Division of General
Dermatology, Department of Dermatology, University of Vienna Medical
School, Wa¨hringer Gu¨rtel 18–20, A-1090 Vienna, Austria.
Abbreviations: dp, desmoplakin; EM, erythema multiforme; IEM, immuno-
electronmicroscopy; IF, immunofluorescence; SPOTs, simple precise original
test system; TBS, Tris buffered saline.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
503
injections into newborn mice, affinity-purified human
autoantibodies and anti-peptide rabbit IgG were detected
on desmosomal plaques of keratinocytes overlying the
injection site. Histologic and electron microscopic exam-
inations showed hydropic degeneration of basal and
suprabasal keratinocytes, dyskeratosis, signs of suprabasal
acantholysis, and keratin filaments detached from the
desmosomal plaques clumping around the nucleus. We
demonstrate that autoantibodies are directed to an epi-
tope within a dp domain crucial for the interaction of
keratin filaments with desmosomes, and, when injected
subcutaneously into newborn mice, produce pathologic
changes. These findings imply that autoantibodies to dp
could impair the function of desmosome – keratin fila-
ment complexes suggesting a pathogenic role in vivo.
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compartment, the desmoglea, and intracellular dense plaques (Schwarz
et al, 1990). Cell adhesive capacity requires both the desmoglea, where
transmembrane cadherins allow for homotypic protein binding, and
the desmosomal plaques, which are assembling sites for intermediate
filaments, e.g., keratin filaments in the epidermis (Green and Jones,
1990; Green et al, 1992; Kouklis et al, 1994).
The assembly of keratin filaments with the desmosomal plaque is
mediated by dp I and II, two constitutive desmosomal plaque proteins
(Mueller and Franke, 1983; O’Keefe et al, 1989). Dp I consists of an
α-helical coiled coil rod domain of around 130 nm length with
heptad repeats similar to the two chained coiled coil rod domains of
intermediate filaments. Globular subdomains on either end of the rod
correspond to the amino and carboxy terminus of the molecule (Green
et al, 1990). Dp II is derived from a spliced mRNA, identical to dp I
except for a shortened rod domain (Green et al, 1990). The NH2-
terminus of dp is necessary for the integration of dp within the
desmosome, whereas the COOH terminus mediates the assembly of
keratin filaments to the desmosomal plaque (Stappenbeck and Green,
1992; Stappenbeck et al, 1993). This coalignment of dp with keratin
filaments requires the 68 amino acids at the extreme end of the carboxy
terminus of dp (Stappenbeck et al, 1993, 1994). If cells are transfected
with carboxy terminus truncated dp, the keratin filaments do not
assemble with the desmosomes but clump into dense bundles that are
arranged around the nuclei of keratinocytes (Bornslaeger et al, 1996).
Similar ultrastructural observations of a disassembly of keratin filaments
from desmosomes and subsequent perinuclear clumping of filaments,
represent a characteristic feature of dyskeratotic cells within EM lesions
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(Orfanos et al, 1974) and were also found in our patients with EM
major and anti-dp I and II autoantibodies.
Based on these observations we asked the question whether the
extreme end of the dp carboxy terminus may serve as an antigenic
binding site for circulating anti-dp autoantibodies. Such binding could
interfere with dp function, consecutively leading to a disturbance of
the keratin filament-desmosome assembly.
In this study we show that an antigenic epitope within the extreme
end of the carboxy terminus of dp is recognized by human anti-dp
autoantibodies. Synthetic peptides representing this amino acid motif
were used for affinity purification of human autoantibodies and as
antigen to raise peptide-specific rabbit antibodies. After subcutaneous
injection into newborn mice these antibodies bind to the desmosomal
plaques of keratinocytes overlying the site of injection accompanied
by apparent cell damage of individual keratinocytes, dyskeratosis, and
suprabasal cleft formation as well as perinuclear clumping of intermediate
filaments. We therefore assume that the presence of anti-dp I and II
autoantibodies in a subset of patients with EM major directed to an
amino acid motif within the extreme end of the carboxy terminus of
dp, does not simply represent an immunologic epiphenomenon but
might contribute to the pathogenetic events operative in that disease.
MATERIALS AND METHODS
Human sera and autoantibodies Sera of four patients with EM major and
defined circulating anti-dp I and II autoantibodies (patients 1–4) characterized
as described in detail previously (Foedinger et al, 1995, 1996) were used. IgG
fractions of sera were isolated on protein A/G sepharose (ImmunoPure
Immobilized ProteinA/G Gel, Pierce, Rockford, IL). For controls, sera or IgG
fractions from patients with pemphigus vulgaris, bullous pemphigoid, and EM
major without anti-dp autoantibodies and from healthy volunteers were
employed.
Preparation of immobilized overlapping synthetic peptides (SPOTs
assay) SPOTs (simple precise original test system) (Frank, 1992) is a technique
that allows the solid phase synthesis of a large number of peptides in a format
suitable for the systematic analysis of antibody epitopes. The SPOTs Kit
(Genosys Biotechnologies, Cambridge, U.K.) contains a ready to use membrane
with 96 preformed spots in which a single amino acid is conjugated to the
cellulose matrix as an anchoring site for peptides, as well as technical equipment,
chemical reagents, and software. The peptides were synthesized manually on
these spots by a specialized peptide synthesis protocol according to the
manufacturer’s instructions (SPOTs Manual, Genosys Biotechnologies). Peptides
from the 68 amino acids at the very carboxy terminus of dp were arranged.
This sequence was entered into the software program and a SPOTscan schedule
to give 59 spots, creating overlapping peptides of the length of 10 amino acids
each, offset by 1, was generated.
Epitope mapping on SPOTs membrane SPOTs membranes containing
overlapping synthetic peptides were used to probe antibodies for identification
of antibody binding sites within the extreme end of the carboxy terminal
domain of dp. Five different membranes were reused not more than six times
each without a fall off in signal intensity. After washing with Tris buffered
saline (TBS), pH 8.0, two membranes were incubated overnight at room
temperature in T-TBS (0.05% Tween-20 in TBS), pH 8.0, containing concen-
trated membrane blocking buffer (Genosys Biotechnologies) and 5% sucrose
(Sigma, St. Louis, MO). To avoid unspecific background binding, IgG fractions
(6 mg per ml) from the sera of patients 1 and 2 diluted 1:50 in blocking buffer,
were used as first antibody and each added to one of the membranes for 5 h,
at room temperature. The membranes were washed and incubated with β-
galactosidase conjugated goat anti-human IgG (Genosys Biotechnologies),
diluted 1:20, for 2 h at room temperature. After washing with T-TBS
(1 3 10 min) followed by phosphate-buffered saline (PBS) (2 3 10 min) the
membranes were exposed to the appropriate signal development solution
containing potassium ferricyanide (Sigma), 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (Sigma), and dimethylformamide (Baker, Deventer, The
Netherlands), prepared as described in the SPOTs manual, for 20 min. Antibody
binding was visualized by the appearance of blue spots. After use, the membranes
were regenerated according to the protocol. To document absence of prebound
IgG and of nonspecific interaction of immobilized peptides with the
β-galactosidase conjugated secondary antibody, the membranes were incubated
in second step antibodies only, followed by washing, signal development, and
regeneration. In addition, IgG from EM major patients 3 and 4 were probed
according to the same protocol.
To test the polyclonal rabbit antibody generated as described below, a
membrane was probed with the rabbit anti-peptide IgG, isolated on A/G
sepharose (ImmunoPure Immobilized Protein A/G Gel, Pierce) to 5 mg per
ml, diluted 1:50, followed by β-galactosidase conjugated goat anti-rabbit IgG
antibody according to the same protocol.
For control, IgG fractions from sera of patients 1 and 2 depleted of
peptide-specific autoantibodies, from patients with EM major without anti-dp
autoantibodies, with pemphigus vulgaris, and with bullous pemphigoid, and
from healthy volunteers as well as from rabbit preimmune serum, were used as
first antibody. In addition, SPOTs membranes were incubated with affinity-
purified peptide-specific human autoantibodies from patient 1, patient 2, and
the rabbit anti-peptide IgG in the presence and absence of a 10-fold excess of
the free synthetic peptide GNSSYSYSYSFS (piChem, R&D, Graz, Austria).
Synthetic peptides, affinity purification of peptide-specific human
autoantibodies, and production of anti-peptide rabbit antibody Twelve
amino acids comprising fraction 1735–1746 (GNSSYSYSYSFS) of dp (Green
et al, 1990) containing the peptide sequence recognized by the human anti-dp
autoantibodies in the SPOTs assay, were synthesized on a beaded polystyrene
polyoxyethylene graft copolymer resin with a coupling intensity of 0.4 mmol
per g (by piChem, R&D; Butz et al, 1994). Two hundred milligrams of that
gel-matrix were loaded onto a 10 ml disposable column (Pierce), swollen in
70% ethanol, and conditioned with 10 mM Tris/HCl, pH 7.4. Sera of patients
1 and 2 were each incubated for 2 h at room temperature, under gentle shaking,
washed with 20 column volumes of Tris/HCl, pH 7.4, followed by washing
with 20 column volumes of Tris/HCl, pH 7.4, containing 0.5 M NaCl.
Antibodies were eluted with 20 mM glycine-HCl, pH 2.9, and rapidly
neutralized with 1 M Tris-HCl, pH 8.0. Sera were passed through the columns
a total of 10 times. Eluted antibodies were pooled, dialyzed against PBS, pH 7.4,
and concentrated to 1 mg per 150 µl with Centricon-10 microconcentrators
(Amicon, Beverly, MA). The sera depleted of peptide-specific autoantibodies
were collected, and IgG fractions were isolated on a protein A/G sepharose
column and used for control experiments.
In addition, a multiple antigenic peptide consisting of amino acids GNSSYSY-
SYSFS synthesized on branched oligo-lysines as carrier was produced (piChem,
R&D) and used as antigen to raise an anti-peptide rabbit antibody (Posnett
et al, 1988; Butz et al, 1994). Rabbits were purchased and immunized by
Charles River (Kisslegg, Germany).
Immunoprecipitation Protein lysates of biosynthetically labeled cultured
human keratinocytes were prepared and immunoprecipitation was performed
as described previously (Stanley et al, 1982, 1984). Briefly, C14-labeled cells
were extracted in 1% NP-40 (Calbiochem-Novabiochem, La Jolla, CA) in TBS
with 2 mM phenylmethylsulfonyl fluoride (Sigma), and proteinase inhibitors,
centrifuged, and preabsorbed with protein A-bearing staphylococci (Pierce).
After incubation with the respective antibody solution, i.e., sera of patients 1
and 2, affinity-purified peptide-specific human autoantibodies, as well as sera
of patients 1 and 2 after depletion of peptide-specific IgG, anti-peptide rabbit
antibody, normal human serum from healthy volunteers, or mouse monoclonal
antibody to dp I and II (clone 2.15; dp 2.15; Progen, Heidelberg, Germany),
the antigen-antibody complexes were precipitated with staphyloccocal protein
G-sepharose (Sigma) and separated by 5% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis slab-gels. The precipitated antigens were visualized by
autoradiography.
Passive transfer of human and rabbit antibodies into newborn BALB/
C mice The animal experimental protocols were approved by the Review
Board of the University of Vienna Medical School and authorized by the
Austrian Ministry of Science. In pilot experiments we had determined a minimal
concentration of 1 mg per 150 µl of antibody to cause morphologic changes
within the injected skin. We performed experiments employing heat-inactivated
serum samples of patients 1 and 2 with EM major and anti-dp autoantibodies,
as well as affinity-purified peptide-specific human autoantibodies, anti-peptide
rabbit serum, and anti-peptide rabbit IgG. Newborn BALB/C mice (total
number n 5 54) were injected subcutaneously into the back skin with 150 µl
of serum from patients 1 (n 5 9) and 2 (n 5 9) or rabbit serum (n 5 9),
150 µl of affinity-purified peptide-specific human autoantibodies of patients 1
(n 5 9) and 2 (n 5 9) or of rabbit IgG (n 5 9), dissolved in PBS at a
concentration of µ1 mg per 150 µl. For repeated injections, we remained
exactly at the same site. The total number of mice in one set of experiment
was divided into three groups (A, B, C in Table I). In one group (A), the
animals were sacrificed by cervical dislocation 24 h after the first injection. The
remaining mice were reinjected at the same site with the respective antibody.
In a second group the animals were sacrificed 24 h later (B), when a third
injection was given to the remaining mice (C) under the same conditions. After
24 h these animals (C) were also sacrificed. Skin biopsies were collected
immediately after sacrification and processed for light and electron microscopy
as well as for immunomorphologic studies described below. For control
experiments, we injected a total number of 48 newborn mice subcutaneously
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Table I. Passive transfer studies in experimental mice
Antibody samples Serum of Serum of Peptide-specific Peptide-specific Rabbit anti- Rabbit anti-
patient 1 patient 2 IgG of patient 1 IgG of patient 2 peptide serum peptide IgG
Groups of mice:a A B C A B C A B C A B C A B C A B C
DIF:b desmosomal staining 1c 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Dyskeratosis – 11 11 – 1 1 – 11 11 – 11 11 – 11 11 – 1 1
Suprabasal acantholysis – 11 11 – 1 1 – 1 1 – 1 1 – 11 11 – 11 1
Hydropic degeneration of – 1 1 – 1 1 – 11 1 – 11 1 – 1 1 – 1 1
basal and suprabasal cells
Focal epidermal necrosis – 11 11 – 1 1 – 1 1 – 1 1 – 1 1 – 1 –
Edema –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1
Dermal infiltrate –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1
aA, B, C indicate groups of mice, with injections given once (A), twice (B), and three times (C) into the back skin at intervals of 24 h.
bDIF, direct immunofluorescence of mouse epidermis overlying the injection site.
c–, not found; 1, found; 11, pronounced finding.
with IgG fractions of sera of patients 1 (n 5 6) and 2 (n 5 6) after depletion
of peptide-specific autoantibodies as well as serum and IgG of two normal
healthy volunteers (n 5 24) or rabbit preimmune serum (n 5 6) and IgG
(n 5 6) according to the experimental protocol as above.
Light and electron microscopy The specificity of affinity-purified peptide-
specific human autoantibodies and rabbit antibodies was tested by indirect
immunofluorescence (IF) and immunoelectron microscopy (IEM) on normal
human skin obtained from healthy volunteers and normal mouse skin. Biopsies
were divided into two parts and processed for IF and postembedding IEM
following the methods routinely used in our laboratory (Tokuyasu, 1985;
Rappersberger et al, 1992). Newborn BALB/C mice were sacrificed by cervical
dislocation and skin samples overlying the site of injection as well as untreated
skin distant from the injection site were prepared for IF, for IEM, and for
routine histology as well as for routine electron microscopy as described in
detail previously (Rappersberger et al, 1990). For histologic evaluation serial
sections of paraffin-embedded biopsy specimens were examined.
Immunofluorescence For indirect IF, 4 µm cryostat sections of normal
human and mouse skin were incubated with sera of patients 1 and 2 as well as
affinity-purified peptide-specific human autoantibodies from these patients
(diluted 1:10 in PBS) or peptide-specific rabbit IgG (diluted 1:80), washed, and
further exposed to fluoroscein isothiocyanate-conjugated goat F(ab)2 anti-
human or anti-rabbit IgG (Cappel, West Chester, PA). For control, sections of
normal human skin were incubated with peptide-specific anti-dp autoantibodies
from patients 1 and 2 and rabbit anti-peptide IgG in the presence of a 10-fold
excess of free synthetic peptide as well as with serum depleted of peptide-
specific autoantibodies. In addition, cryostat sections of normal human skin
were incubated with serum samples (diluted 1:5 in PBS) of antibody-injected
mice followed by appropriate goat anti-human or anti-rabbit reporter antibodies
to test for the presence of circulating injected antibodies in experimental animals.
For direct IF, cryostat sections of lesional mouse skin injected with anti-dp
antibodies and controls as detailed in the passive transfer protocol were quenched
in PBS, pH 7.4, containing 1% bovine serum albumin (Sigma) and exposed to
fluoroscein isothiocyanate-conjugated goat F(ab)2 anti-human or anti-rabbit
IgG (Cappel). As additional control, untreated mouse skin obtained distant
from the injection site was processed.
Immunoelectron microscopy Immunogold labeling on ultrathin cryosec-
tions was performed as described in detail previously (Tokuyasu, 1985;
Rappersberger et al, 1992). Briefly, for indirect immunogold labeling ultrathin
cryosections of normal human skin were quenched in PBS/50 mM glycine
(BioRad Laboratories, Richmond, CA)/10% fetal calf serum (GIBCO-BRL,
Gaithersburg, MD), consecutively incubated with affinity-purified peptide-
specific human or anti-peptide rabbit IgG, washed, and further exposed to goat
anti-human or goat anti-rabbit IgG conjugated to 10 nm colloidal gold particles
(Amersham, Bucks, U.K.). For control, sections were incubated with normal
human IgG or preimmune rabbit IgG as first antibodies. For direct immunogold
labeling, ultrathin cryosections of lesional mouse skin injected with affinity-
purified peptide-specific human IgG or rabbit anti-peptide IgG were quenched
and exposed to goat anti-human or anti-rabbit IgG gold conjugates. The
specimens were washed, counterstained, embedded, and examined using a
JEOL 1200 EX electron microscope.
RESULTS
Anti-dp I and II autoantibodies of EM major patients recognize
a peptide domain within the carboxy terminus of
dp Investigations of globular and rod domains of dp have suggested
that the 68 amino acids at the extreme end of the carboxy terminus
are necessary for the coalignment of keratin filaments with the
desmosomal plaque (Stappenbeck et al, 1993). Pathogenetic relevance
of autoantibodies would most likely require their interaction with a
functional domain of the respective antigen. To probe whether this
crucial domain of dp could be the target of the human anti-dp
autoantibodies, we performed epitope mapping on SPOTs membranes
containing the last 68 amino acids of the carboxy terminus of
dp, disassembled into 59 overlapping 10-meric synthetic peptides.
Specificity of autoantibodies was tested by immunoblotting of SPOTs
membranes with IgG fractions of patients’ sera. IgG from the EM
major patients with circulating anti-dp autoantibodies specifically
recognize a cluster of spots corresponding to the hexapeptide YSYSYS
representing amino acids 1739–1744 (Fig 1a, b, e) at the extreme end
of the carboxy terminus of dp.
In addition, a peptide was synthesized representing the epitope
identified by the human autoantibodies. To obtain an account of the
variability of both borders of this peptide in the SPOTs assay, the
sequence of the synthetic peptide was extended by four amino acids
at the NH2 terminus and two amino acids on the COOH terminus,
respectively, comprising amino acids 1735–1746 of dp (GNSSYSYS-
YSFS). This peptide was used as matrix for affinity purification of human
serum autoantibodies and as antigen to raise polyclonal antibodies in
a rabbit. When the SPOTs membranes were immunoblotted with both
affinity-purified peptide-specific human autoantibodies and rabbit anti-
peptide IgG, almost identical clusters of spots were recognized corres-
ponding to the consensus sequence YSYSYS (Fig 1c, e), whereas no
signal appeared in the presence of the corresponding free synthetic
peptide. In addition, no specific signals were generated after immunob-
lotting with IgG fractions from sera of patients 1 and 2 depleted of
peptide-specific autoantibodies, from IgG fractions from patients with
EM major without anti-dp autoantibodies, from patients with pem-
phigus vulgaris (Fig 1d) or bullous pemphigoid, from healthy volun-
teers, and from rabbit preimmune IgG.
Affinity-purified peptide-specific human autoantibodies and
anti-peptide rabbit antibodies recognize intact dp I and II and
bind to desmosomes The specificity of human and rabbit antibodies
was examined by immunoprecipitation of biosynthetically C14-labeled
cultured human keratinocytes. Affinity-purified peptide-specific human
autoantibodies and anti-peptide rabbit IgG bound to polypeptides of
250 kDa and 210 kDa, representing dp I and II, as indicated by control
precipitation with monoclonal antibody dp2.15 (Fig 2, lanes d–g).
Immunoprecipitation with sera of patients 1 and 2 depleted of peptide-
specific autoantibodies showed only weak reactivity at 250 kDa and
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Figure 1. Epitope mapping on SPOTs membranes representing the 68
amino acids at the extreme end of the COOH terminus of dp reveals
YSYSYS as target sequence for EM autoantibodies. Immunoblotting with
IgG fractions of patient 1 (a) and patient 2 (b) shows strong reactivity with
spots 51–55. The same cluster of spots was labeled when rabbit anti-peptide
IgG was applied (c). For control, IgG fractions of a patient with pemphigus
vulgaris was immunoblotted, showing no reactivity on these spots (d). The
consensus sequence as recognized by reactive antibodies is given in (e).
210 kDa, indicating the presence of remaining low titer anti-dp
autoantibodies after depletion of peptide-specific autoantibodies (Fig 2,
lane h).
Indirect IF with sera and peptide-specific human autoantibodies of
Figure 2. Immunoprecipitation. Protein extracts of radiolabeled cultured
human keratinocytes were immunoprecipitated with sera of patients 1 (lane b)
and 2 (lane c), affinity-purified peptide-specific human IgG of patients 1 (lane
d) and 2 (lane e), and rabbit anti-peptide IgG (lane f). Precipitated proteins
represent dp I and II as shown by control precipitation with monoclonal
antibody dp 2.15 (lane g). Lane h shows immunoprecipitation with serum of
patient 1 after depletion of peptide-specific autoantibodies recognizing only
traces of dp I and II. Lanes i and j show absence of reactivity with normal
human IgG and rabbit preimmune IgG, respectively. Lane a gives a high
molecular weight standard indicating 200 kDa.
patients 1 and 2 and anti-peptide rabbit IgG performed on normal
human and normal mouse skin revealed identical results: in all cases
we observed a distinct dotted desmosomal staining pattern along the
cytoplasmic membranes of keratinocytes (Fig 3a–c). When human
skin sections were incubated with affinity-purified peptide-specific
autoantibodies of patients 1 and 2, or rabbit anti-peptide IgG in the
presence of free synthetic peptide, no desmosomal fluorescence signal
could be observed (Fig 3d). Patient’s sera depleted of peptide-specific
autoantibodies gave only a weak membrane staining of keratinocytes
when indirect IF was performed on normal human skin (not shown).
The specificity of the affinity-purified peptide-specific human
autoantibodies and anti-peptide rabbit IgG was further confirmed by
postembedding immunogold IEM studies on ultrathin cryosections of
normal human skin. The ultrastructural binding sites of human and
rabbit IgG could be clearly confined to the cytoplasmic inner dense
plaques of desmosomes (Fig 3e, f). Normal human IgG and rabbit
preimmune IgG did not give any specific labeling in indirect IF
and IEM.
Passive transfer of antibodies into newborn BALB/C mice We
have previously shown that human anti-dp autoantibodies of patients
with EM major subcutaneously injected into newborn BALB/C mice
appear within mouse epidermis after a period of 18 h (Foedinger et al,
1995). In order to further test the effect of these antibodies we now
injected whole patients’ sera containing anti-dp autoantibodies, affinity-
purified peptide-specific human autoantibodies, anti-peptide rabbit
serum, as well as rabbit IgG, subcutaneously into the back skin of
newborn BALB/C mice.
Examination of the mouse skin revealed a mild cutaneous erythema
after the second and third injection that was restricted to the injection
site. Direct IF and IEM of skin samples taken after one, two, and three
injections of the respective antibodies demonstrated similar changes:
by direct IF we observed a characteristic dotted desmosomal staining
pattern of the entire murine epidermis (Fig 4a–e). In addition, direct
IEM localized the binding of human and rabbit IgG to the innermost
portion of murine desmosomal plaques facing the cytosol (Fig 4g–i).
Histomorphology of skin biopsies taken 24 h after the first injection
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Figure 3. Indirect immunolabeling of normal human skin. A distinct dotted desmosomal staining pattern is seen after probing sera of patient 1 (a), affinity-
purified peptide-specific IgG of patient 1 (b), and rabbit anti-peptide IgG (c). When cryostat sections of normal human skin were incubated with peptide-specific
IgG of patient 1 in the presence of excess free synthetic peptide, no desmosomal staining pattern could be observed (d). On ultrathin cryosections peptide-specific
autoantibodies (e) as well as rabbit anti-peptide IgG (f) indicated by 10 nm colloidal gold particles are associated with the inner dense plaques of desmosomes were
keratin filaments insert. Scale bars: (a–d) 20 µm; (e, f) 0.2 µm.
Figure 4. Direct immunolabeling of lesional mouse skin after antibody
injection. Direct IF shows the characteristic desmosomal staining pattern of
the entire murine epidermis 24 h after subcutaneous injection into mouse skin
of serum from EM major patients 1 (a) and 2 (d), affinity-purified peptide-
specific antibody of patients 1 (b) and 2 (e), and anti-peptide rabbit IgG (c).
Injection of IgG from patient 1 after depletion of peptide-specific autoantibodies
gave no desmosomal staining pattern (f). Direct IEM on ultrathin cryosections
of lesional mouse skin confines the human (g, h) as well as the rabbit IgG (i)
to the inner portion of the desmosomal plaque. Scale bars: (a–f) 40 µm; (g–
i) 0.1 µm.
did not reveal any pathology; however, biopsies taken 24 h after the
second and third injection showed moderate to severe changes of the
murine epidermis overlying the site of injection. Biopsy specimens
displayed numerous dyskeratotic keratinocytes and colloid bodies,
signs of a pronounced hydropic degeneration of basal and suprabasal
keratinocytes, that focally evolved to necrosis of basal and suprabasal
cell layers (Fig 5a–e). In addition, we detected a loss of intercellular
adhesion among individual keratinocytes and disaggregation of supraba-
sal from basal cells leading to suprabasal cleft formation (Fig 5e).
Within the dermis of lesional mouse skin we found local edema and
an inflammatory lymphohystiocytic infiltrate with an admixture of
neutrophils. Results of passive transfer experiments are summarized
in Table I.
By electron microscopy we found disintegrated rounded ker-
atinocytes that showed intact cell membranes almost completely devoid
of regular desmosome–keratin filament complexes. The desmosomes
appeared intact and were still integrated into the cell membrane but
lacked the association of keratin filaments. Within the cytoplasm of
such cells keratin filaments appeared as clumped, condensed bundles
aggregated around the nucleus (Fig 6).
Control experiments as summarized in Table II did not give any
desmosomal staining after injection and did not result in any significant
epidermal changes. We only found a mild edema and inflammatory
infiltrate at the site of injection. Skin samples distant from the injection
site showed neither morphologic alterations nor antibody binding.
Circulating injected antibodies could be detected in mouse blood
samples only at low titer when tested by indirect IF on cryostat sections
of normal human skin.
DISCUSSION
EM major is a skin disease characterized by the occurrence of extensive
mucocutaneous erythemas that are accompanied by blisters and painful
erosions (Huff et al, 1983). Previous immunologic studies have strongly
favored the concept that the pathomechanisms leading to the destruction
of epithelial cells are predominantly mediated by a cellular immune
response via cytotoxic T cells (Margolis et al, 1983; Tonnesen et al,
1983). In two recent reports we have demonstrated the presence of
circulating autoantibodies directed against the desmosomal plaque
proteins dp I and II that bound to keratinocytes of skin- and mucosal
lesions in a subset of patients with EM major (Foedinger et al, 1995,
1996). These findings have suggested that, in addition to a cellular
immune response, humoral immune mechanisms may be involved in
the pathogenesis of certain patients with this disease (Stanley, 1995).
Recent molecular investigations have shown that desmosomes of
A431 epithelial cells transfected with deletion constructs of dp, lacking
the COOH-terminal domain, fail to assemble with keratin filaments:
such cells display desmosome-like adherens junctions along the cell
membrane with well-developed desmosomal plaques (Bornslaeger et al,
1996). These plaques, however, lack the association with keratin
filaments that are condensed into clumps and aggregated around the
nucleus, suggesting that the deleted amino acid portion of dp is
required for the regular organization of the keratin filament–desmosome
complexes (Stappenbeck and Green, 1992; Bornslaeger et al, 1996).
Because disassembly of desmosomes and keratin filaments and clumping
around the nucleus have also been described in human EM lesions
(Orfanos et al, 1974) and have been observed in EM patients with
anti-dp autoantibodies, the question arose whether human anti-dp
autoantibodies are directed against an epitope within the functional
domain of dp described to be responsible for keratin interaction
(Stappenbeck et al, 1993). Following this assumption, anti-dp autoanti-
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bodies could interfere with functional properties of desmosome-
intermediate filament complexes and subsequently impair cell morpho-
logy and behavior.
Immunochemical peptide mapping of the 68 amino acid residue at
Figure 5. Histopathology of lesional mouse skin after antibody injection.
Following two consecutive injections with serum of patient 2 (a) we could
observe dyskeratosis and focal necrosis of the epidermis. Part (b) shows
dyskeratosis, focal necrosis, and blister formation after two injections with serum
of patient 1. The blister floor is formed by flattened keratinocytes indicating
regeneration (b). Dyskeratotic cells are shown after the injection of affinity-
purified peptide-specific autoantibodies of patient 1 (c) and anti-peptide rabbit
antibody (e). These cells display a condensed eosinophilic cytoplasm and
pyknotic nuclei and had lost their intercellular contacts with neighboring cells
(c, e, arrows). In (d), focal epidermal necrosis is shown after injection of serum
of patient 2. Early signs of suprabasal cleft formation are seen in (e; open arrows).
Part (f) shows unaltered skin of a newborn BALB/C mouse injected with
IgG fractions from serum of patient 1 after depletion of peptide-specific
autoantibodies. Scale bars: 20 µm.
Table II. Control experiments of passive transfer studies in mice
Antibody samples Normal human IgG of patient 1, IgG of patient 2,
Sera of 2 healthy IgG of 2 healthy depleted of anti- depleted of anti- Rabbit Rabbit
volunteers volunteers peptide-Ig6 peptide-IgG preimmune serum preimmune IgG
Groups of mice:a A B C A B C A B C A B C A B C A B C
Number of injected mice 4 4 4 4 4 4 2 2 2 2 2 2 2 2 2 2 2 2
DIFb –c – – – – – – – – – – – – – – – – –
Edema –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1
Dermal infiltrate –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1 –/1 1 1
Epidermal alterations – – – – – – – – – – – – – – – – – –
aA, B, C indicate groups of mice, with injections given once (A), twice (B), and three times (C) into the back skin at intervals of 24 h.
bDIF, direct immunofluorescence showing desmosomal staining pattern of mouse epidermis overlying the injection site.
c–, not found; 1, found.
the very carboxy terminus of dp on SPOTs membranes revealed that
the human anti-dp I and II autoantibodies recognize a distinct epitope,
consisting of a YSYSYS motif representing amino acids 1739–1744 of
dp (Green et al, 1990). As a consequence, we synthesized corresponding
peptides for affinity purification of human autoantibodies and as
antigen to generate rabbit anti-peptide antibody; subsequently we
could demonstrate that both affinity-purified peptide-specific human
autoantibodies and rabbit anti-peptide IgG bind to identical clusters of
spots on the membranes, confirming the authenticity of the identified
sequence. Moreover, both antibodies specifically recognize dp I and
II by immunoprecipitation and localize to desmosomes and desmosomal
plaques on normal human skin by light and electron microscopy.
In a next set of experiments we tested for potential pathobiologic
relevance of human and rabbit anti-dp antibodies in vivo by injecting
the antibodies subcutaneously into newborn mice. The technique and
time course of the injections and the amount of antibodies used was
determined in accordance with recent reports that investigated the
pathogenicity of human autoantibodies of patients with epidermolysis
bullosa acquisita (Borradori et al, 1995) and with microinjection studies
of anti-keratin antibodies into living cells (Klymkowsky et al, 1983).
After repeated injections of patients’ whole sera, affinity-purified
peptide-specific human anti-dp autoantibodies as well as rabbit anti-
peptide antibody, but not in control experiments, we observed histo-
morphologic alterations reminiscent of human EM lesions, like pro-
nounced hydropic degeneration of basal and suprabasal keratinocytes,
dyskeratotic cells, colloid bodies, and suprabasal acantholytic cleft
formation within the murine epidermis overlying the site of injection.
Further ultrastructural examinations demonstrate the presence of ker-
atinocytes that display intact cell membranes and desmosomes, with
Figure 6. Ultrastructure of individual keratinocytes within lesional
mouse epidermis. By electron microscopy affected cells show shrinkage of
nuclei and a condensation of keratin filaments that were mostly disassembled
from desmosomes (arrows) but found as dense, filamentous aggregates around
the nucleus (arrowheads). Scale bar: 1 µm.
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well-developed desmosomal plaques lacking the coalignment with
keratin filaments that had clumped into electron dense bundles that
were aggregated around the nucleus. The observation that antibody
binding to dp was already visible by direct IF 24 h after the first
injection, but that histomorphologic changes could only be observed
after repeated subcutaneous injections, suggests that high concentrations
of antibodies over a prolonged period of time are necessary to induce
these alterations. The time course of these in vivo experiments appears
reasonable in relation to in vitro experiments using direct microinjection
of anti-keratin antibodies into epithelial cells, when several hours were
necessary to develop disassembly of the keratin filament network and
injected antibodies were detectable up to 4 d within otherwise intact
cells (Klymkowsky et al, 1983). Skin samples distant from the injected
area did not reveal any alteration in IF and histology. Although injected
circulating antibodies are found in blood samples of experimental mice
at low titer, no generalized skin lesions could be observed. This can
be explained by the fact that injected antibodies are present at
concentrations too low to sufficiently reach their antigenic target. In
addition, the epidermal injury with local edema and inflammatory
reaction at the injection site itself might favor antibody access and
support morphologic changes.
Considering these findings alongside recent reports (Vassar et al,
1991; Klymkowsky et al, 1992; Bornslaeger et al, 1996) that demonstrate
a perturbation of the desmosome-intermediate filament complexes by
antibody injection and/or expression of mutant proteins only in
complex epithelia in vivo, but not in cell culture, one could imagine the
following scenario: supported by a local reaction, anti-dp autoantibodies
reach the epidermis and enter individual keratinocytes; once inside the
cells they subsequently bind to accessible binding sites on the carboxy
terminus of dp and thereby interfere with the coalignment of dp with
keratin filaments that consecutively collapse into bundles and clump
around the nucleus.
Although we clearly show by IEM that subcutaneously injected
peptide-specific human autoantibodies and anti-peptide rabbit antibod-
ies bind to the desmosomal plaques within keratinocytes, indicating
antibody penetration into the cells, the question of possible penetration
mechanisms remains to be clarified. There exist several lines of evidence
that autoantibodies may penetrate living cells in vivo (Gallopin and
Saurat, 1981; Alarco´n-Segovia et al, 1996). For example, studies with
anti-nuclear antibodies of patients with systemic lupus erythematosus
indicate IgG antibody penetration into living epithelial cells via
receptor-mediated endocytosis and intracellular relocation to reach
their antigen (Golan et al, 1993). Thus, one could imagine that anti-
dp autoantibodies bind to the cell surface of individual keratinocytes
within the epidermis, followed by internalization and consecutive
binding to the cytoplasmic desmosomal plaques. In preliminary injection
experiments using the free synthetic peptide GNSSYSYSYSFS at
concentrations similar to that of peptide-specific IgG, we were unable
to induce morphologic alterations within the epidermis overlying the
injection site (not shown). Small synthetic peptides might not be
able to interfere directly with complex protein–protein interactions
compared with larger antibody molecules. The interaction of keratin
filaments with the desmosomal plaque at the COOH-terminal domain
of dp is more complex and other peptide domains or conformational
factors may play a role (Stappenbeck et al, 1993, 1994). Further
experiments will be necessary to investigate mechanisms of antibody
access into keratinocytes and of local antibody interaction and effects.
Taken together, in this study we show that human autoantibodies
against dp I and II of a subset of patients with EM major recognize an
epitope within the carboxy terminal domain of dp. These antibodies
bind to desmosomal plaques of keratinocytes in vivo after subcutaneous
injection into newborn mice. The observation of impaired desmosome–
keratin filament complexes in affected keratinocytes provides support
for our hypothesis that anti-dp autoantibodies could contribute to the
pathomechanism operative in EM major.
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